IP Library › Granted Patent US 12,391,764
Granted Patent B2
US 12,391,764 · App. 18/301,924 · Granted Aug 19, 2025

Anti-CD30 and anti-CD3 bispecific antibodies and methods of immunotherapy for CD30+ malignancies

Inventors: Jeffrey A. Medin (Shorewood, WI); Lawrence G. Lum (Charlottesville, VA); Robyn A. A. Oldham (Milwaukee, WI); Archana Thakur (Charlottesville, VA)
Assignees: The Medical College of Wisconsin, Inc.; University of Virginia Patent Foundation
C07K16/2878A61K39/39583A61P35/00C07K16/2809A61K39/3955C07K14/7051C07K14/70578C07K16/283C07K2317/31C07K2317/565C07K2317/732
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,391,764
App. No.
18/301,924
Granted
Aug 19, 2025
Kind
B2
Abstract

The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.

Claims (74)

1. An isolated bispecific antibody capable of binding human CD30 and to CD3 comprising an anti-CD30 antibody or antigen binding portion thereof and an anti-CD3 antibody or antigen binding portion thereof, wherein the anti-CD30 antibody or antigen binding portion thereof comprises:

(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_2 or a sequence with at least 90% similarity to SEQ ID NO:_2, a CDRL2 region of SEQ ID NO:_3 or a sequence with at least 90% similarity to SEQ ID NO:_3, and a CDRL3 region of SEQ ID NO:_4 or a sequence with at least 90% similarity to SEQ ID NO:_4 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_6 or a sequence with at least 90% similarity to SEQ ID NO:_6, a CDRH2 region of SEQ ID NO:_7 or a sequence with at least 90% similarity to SEQ ID NO:_7, and a CDRH3 region of SEQ ID NO:_8 or a sequence with at least 90% similarity to SEQ ID NO:_8;

(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 90% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 90% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO:_12 or a sequence with at least 90% similarity to SEQ ID NO: 12 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 90% similarity to SEQ ID NO:_14, a CDRH2 region of SEQ ID NO:_15 or a sequence with at least 90% similarity to SEQ ID NO:_15, and a CDRH3 region of GAY or a sequence with at least 90% similarity to GAY;

(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_18 or a sequence with at least 90% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 90% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO:_20 or a sequence with at least 90% similarity to SEQ ID NO:_20 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_22 or a sequence with at least 90% similarity to SEQ ID NO:_22, a CDRH2 region of SEQ ID NO:_23 or a sequence with at least 90% similarity to SEQ ID NO: 23, and a CDRH3 region of SEQ ID NO:_24 or a sequence with at least 90% similarity to SEQ ID NO:_24;

(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_26 or a sequence with at least 90% similarity to SEQ ID NO: 26, a CDRL2 region of SEQ ID NO:_27 or a sequence with at least 90% similarity to SEQ ID NO:_27, and a CDRL3 region of SEQ ID NO:_28 or a sequence with at least 90% similarity to SEQ ID NO:_28 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_30 or a sequence with at least 90% similarity to SEQ ID NO:_30, a CDRH2 region of SEQ ID NO:_31 or a sequence with at least 90% similarity to SEQ ID NO:_31, and a CDRH3 region of SEQ ID NO:_32 or a sequence with at least 90% similarity to SEQ ID NO:_32; or

(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_34 or a sequence with at least 90% similarity to SEQ ID NO:_34, a CDRL2 region of SEQ ID NO:_35 or a sequence with at least 90% similarity to SEQ ID NO:_35, and a CDRL3 region of SEQ ID NO:_36 or a sequence with at least 90% similarity to SEQ ID NO:_36 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_38 or a sequence with at least 90% similarity to SEQ ID NO:_38, a CDRH2 region of SEQ ID NO:_39 or a sequence with at least 90% similarity to SEQ ID NO:_39, and a CDRH3 region of SEQ ID NO:_40 or a sequence with at least 90% similarity to SEQ ID NO:_40.

2. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises:

(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_2 or a sequence with at least 95% similarity to SEQ ID NO:_2, a CDRL2 region of SEQ ID NO:_3 or a sequence with at least 95% similarity to SEQ ID NO:_3, and a CDRL3 region of SEQ ID NO:_4 or a sequence with at least 95% similarity to SEQ ID NO:_4 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_6 or a sequence with at least 95% similarity to SEQ ID NO:_6, a CDRH2 region of SEQ ID NO:_7 or a sequence with at least 95% similarity to SEQ ID NO:_7, and a CDRH3 region of SEQ ID NO:_8 or a sequence with at least 95% similarity to SEQ ID NO:_8;

(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 95% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 95% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO:_12 or a sequence with at least 95% similarity to SEQ ID NO: 12 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 95% similarity to SEQ ID NO:_14, a CDRH2 region of SEQ ID NO:_15 or a sequence with at least 95% similarity to SEQ ID NO:_15, and a CDRH3 region of GAY or a sequence with at least 95% similarity to GAY;

(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_18 or a sequence with at least 95% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 95% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO:_20 or a sequence with at least 95% similarity to SEQ ID NO:_20 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_22 or a sequence with at least 95% similarity to SEQ ID NO:_22, a CDRH2 region of SEQ ID NO:_23 or a sequence with at least 95% similarity to SEQ ID NO:_23, and a CDRH3 region of SEQ ID NO:_24 or a sequence with at least 95% similarity to SEQ ID NO:_24;

(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_26 or a sequence with at least 95% similarity to SEQ ID NO:_26, a CDRL2 region of SEQ ID NO:_27 or a sequence with at least 95% similarity to SEQ ID NO:_27, and a CDRL3 region of SEQ ID NO: 28 or a sequence with at least 95% similarity to SEQ ID NO:_28 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_30 or a sequence with at least 95% similarity to SEQ ID NO:_30, a CDRH2 region of SEQ ID NO:_31 or a sequence with at least 95% similarity to SEQ ID NO:_31, and a CDRH3 region of SEQ ID NO:_32 or a sequence with at least 95% similarity to SEQ ID NO:_32; or

(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_34 or a sequence with at least 95% similarity to SEQ ID NO:_34, a CDRL2 region of SEQ ID NO:_35 or a sequence with at least 95% similarity to SEQ ID NO:_35, and a CDRL3 region of SEQ ID NO:_36 or a sequence with at least 95% similarity to SEQ ID NO:_36 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_38 or a sequence with at least 95% similarity to SEQ ID NO:_38, a CDRH2 region of SEQ ID NO:_39 or a sequence with at least 95% similarity to SEQ ID NO:_39, and a CDRH3 region of SEQ ID NO:_40 or a sequence with at least 95% similarity to SEQ ID NO:_40.

3. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises:

(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_2 or a sequence with at least 98% similarity to SEQ ID NO:_2, a CDRL2 region of SEQ ID NO:_3 or a sequence with at least 98% similarity to SEQ ID NO:_3, and a CDRL3 region of SEQ ID NO:_4 or a sequence with at least 98% similarity to SEQ ID NO:_4 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_6 or a sequence with at least 98% similarity to SEQ ID NO:_6, a CDRH2 region of SEQ ID NO:_7 or a sequence with at least 98% similarity to SEQ ID NO:_7, and a CDRH3 region of SEQ ID NO:_8 or a sequence with at least 98% similarity to SEQ ID NO:_8;

(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 98% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 98% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO: 12 or a sequence with at least 98% similarity to SEQ ID NO: 12 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 98% similarity to SEQ ID NO:_14, a CDRH2 region of SEQ ID NO:_15 or a sequence with at least 98% similarity to SEQ ID NO:_15, and a CDRH3 region of SEQ ID NO: 16 GAY or a sequence with at least 98% similarity to SEQ ID NO:16 GAY;

(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_18 or a sequence with at least 98% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 98% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO:_20 or a sequence with at least 98% similarity to SEQ ID NO:_20 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_22 or a sequence with at least 98% similarity to SEQ ID NO:_22, a CDRH2 region of SEQ ID NO:_23 or a sequence with at least 98% similarity to SEQ ID NO:_23, and a CDRH3 region of SEQ ID NO:_24 or a sequence with at least 98% similarity to SEQ ID NO:_24;

(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_26 or a sequence with at least 98% similarity to SEQ ID NO: 26, a CDRL2 region of SEQ ID NO:_27 or a sequence with at least 98% similarity to SEQ ID NO:_27, and a CDRL3 region of SEQ ID NO: 28 or a sequence with at least 98% similarity to SEQ ID NO:_28 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_30 or a sequence with at least 98% similarity to SEQ ID NO:_30, a CDRH2 region of SEQ ID NO:_31 or a sequence with at least 98% similarity to SEQ ID NO:_31, and a CDRH3 region of SEQ ID NO:_32 or a sequence with at least 98% similarity to SEQ ID NO:_32; or

(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_34 or a sequence with at least 98% similarity to SEQ ID NO:_34, a CDRL2 region of SEQ ID NO:_35 or a sequence with at least 98% similarity to SEQ ID NO:_35, and a CDRL3 region of SEQ ID NO:_36 or a sequence with at least 98% similarity to SEQ ID NO:_36 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_38 or a sequence with at least 98% similarity to SEQ ID NO:_38, a CDRH2 region of SEQ ID NO:_39 or a sequence with at least 98% similarity to SEQ ID NO:_39, and a CDRH3 region of SEQ ID NO:_40 or a sequence with at least 98% similarity to SEQ ID NO:_40.

4. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises:

(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_2, a CDRL2 region of SEQ ID NO:_3, and a CDRL3 region of SEQ ID NO:_4, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_6, a CDRH2 region of SEQ ID NO:_7, and a CDRH3 region of SEQ ID NO:_8;

(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO:_12, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14, a CDRH2 region of SEQ ID NO: 15, and a CDRH3 region of SEQ ID NO: 16 GAY;

(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_18, a CDRL2 region of SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO:_20, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_22, a CDRH2 region of SEQ ID NO:_23, and a CDRH3 region of SEQ ID NO:_24;

(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_26, a CDRL2 region of SEQ ID NO:_27, and a CDRL3 region of SEQ ID NO:_28, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_30, a CDRH2 region of SEQ ID NO:_31, and a CDRH3 region of SEQ ID NO:_32; or

(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_34, a CDRL2 region of SEQ ID NO:_35, and a CDRL3 region of SEQ ID NO:_36, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_38, a CDRH2 region of SEQ ID NO:_39, and a CDRH3 region of SEQ ID NO:_40.

5. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain and a heavy chain comprising:

(a) a light chain comprising SEQ ID NO:_1 or a sequence with at least 90% similarity to SEQ ID NO:_1, and a heavy chain comprising SEQ ID NO:_5 or a sequence with at least 90% similarity to SEQ ID NO:_5;

(b) a light chain comprising SEQ ID NO:_9 or a sequence with at least 90% similarity to SEQ ID NO:_9, and a heavy chain comprising SEQ ID NO:_13 or a sequence with at least 90% similarity to SEQ ID NO:_13;

(c) a light chain comprising SEQ ID NO:_17 or a sequence with at least 90% similarity to SEQ ID NO:_17, and a heavy chain comprising SEQ ID NO:_21 or a sequence with at least 90% similarity to SEQ ID NO:_21;

(d) a light chain comprising SEQ ID NO:_25 or a sequence with at least 90% similarity to SEQ ID NO:_25, and a heavy chain comprising SEQ ID NO:_29 or a sequence with at least 90% similarity to SEQ ID NO:_29; or

(e) a light chain comprising SEQ ID NO:_33 or a sequence with at least 90% similarity to SEQ ID NO:_33, and a heavy chain comprising SEQ ID NO:_37 or a sequence with at least 90% similarity to SEQ ID NO:_37.

6. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain and a heavy chain comprising:

(a) a light chain comprising SEQ ID NO:_1 or a sequence with at least 95% similarity to SEQ ID NO:_1, and a heavy chain comprising SEQ ID NO:_5 or a sequence with at least 95% similarity to SEQ ID NO:_5;

(b) a light chain comprising SEQ ID NO:_9 or a sequence with at least 95% similarity to SEQ ID NO:_9, and a heavy chain comprising SEQ ID NO:_13 or a sequence with at least 95% similarity to SEQ ID NO:_13;

(c) a light chain comprising SEQ ID NO:_17 or a sequence with at least 95% similarity to SEQ ID NO:_17, and a heavy chain comprising SEQ ID NO:_21 or a sequence with at least 95% similarity to SEQ ID NO:_21;

(d) a light chain comprising SEQ ID NO:_25 or a sequence with at least 95% similarity to SEQ ID NO:_25, and a heavy chain comprising SEQ ID NO:_29 or a sequence with at least 95% similarity to SEQ ID NO:_29; or

(e) a light chain comprising SEQ ID NO:_33 or a sequence with at least 95% similarity to SEQ ID NO:_33, and a heavy chain comprising SEQ ID NO:_37 or a sequence with at least 95% similarity to SEQ ID NO:_37.

7. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain and a heavy chain comprising:

(a) a light chain comprising SEQ ID NO:_1 or a sequence with at least 98% similarity to SEQ ID NO:_1, and a heavy chain comprising SEQ ID NO:_5 or a sequence with at least 98% similarity to SEQ ID NO:_5;

(b) a light chain comprising SEQ ID NO:_9 or a sequence with at least 98% similarity to SEQ ID NO:_9, and a heavy chain comprising SEQ ID NO:_13 or a sequence with at least 98% similarity to SEQ ID NO:_13;

(c) a light chain comprising SEQ ID NO:_17 or a sequence with at least 98% similarity to SEQ ID NO:_17, and a heavy chain comprising SEQ ID NO:_21 or a sequence with at least 98% similarity to SEQ ID NO:_21;

(d) a light chain comprising SEQ ID NO:_25 or a sequence with at least 98% similarity to SEQ ID NO:_25, and a heavy chain comprising SEQ ID NO:_29 or a sequence with at least 98% similarity to SEQ ID NO:_29; or

(e) a light chain comprising SEQ ID NO:_33 or a sequence with at least 98% similarity to SEQ ID NO:_33, and a heavy chain comprising SEQ ID NO:_37 or a sequence with at least 98% similarity to SEQ ID NO:_37.

8. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain and a heavy chain comprising:

(a) a light chain comprising SEQ ID NO: 1 and a heavy chain comprising SEQ ID NO:_5;

(b) a light chain comprising SEQ ID NO:_9 and a heavy chain comprising SEQ ID NO: 13;

(c) a light chain comprising SEQ ID NO:_17 and a heavy chain comprising SEQ ID NO:_21;

(d) a light chain comprising SEQ ID NO:_25 and a heavy chain comprising SEQ ID NO:_29; or

(e) a light chain comprising SEQ ID NO:_33 and a heavy chain comprising SEQ ID NO:_37.

9. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof is a monoclonal antibody.

10. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof is directly or indirectly conjugated to the anti-CD3 antibody or antigen binding portion thereof.

11. The isolated bispecific antibody of claim 10 , wherein the anti-CD30 antibody or antigen binding portion thereof is directly conjugated to the anti-CD3 antibody or antigen binding portion thereof.

12. The isolated bispecific antibody of claim 11 , wherein the anti-CD30 antibody or antigen binding portion thereof is directly conjugated to the anti-CD3 antibody or antigen binding portion thereof via a linker.

13. The isolated bispecific antibody of claim 1 , wherein the anti-CD3 antibody is OKT3 made by hybridoma with ATCC accession number CRL 8001.

14. A composition comprising the isolated bispecific antibody of claim 1 and a pharmaceutically acceptable carrier.

15. An isolated bispecific antibody capable of binding human CD30 and CD3 comprising an anti-CD30 antibody or antigen binding portion thereof and an anti-CD3 antibody or antigen binding portion thereof, wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain variable domain comprising a CDRL1 region comprising the sequence of SEQ ID NO:_2, a CDRL2 region comprising the sequence of SEQ ID NO:_3, and a CDRL3 region comprising the sequence of SEQ ID NO:_4, and a heavy chain variable domain comprising the sequence of SEQ ID NO:_6, a CDRH2 region comprising the sequence of SEQ ID NO:_7, and a CDRH3 region comprising the sequence of SEQ ID NO:_8.

16. The isolated bispecific antibody of claim 15 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain comprising SEQ ID NO:_1 or a sequence with at least 95% similarity to SEQ ID NO:_1, and a heavy chain comprising SEQ ID NO:_5 or a sequence with at least 95% similarity to SEQ ID NO:_5.

17. The isolated bispecific antibody of claim 15 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain comprising SEQ ID NO:_1 or a sequence with at least 98% similarity to SEQ ID NO:_1, and a heavy chain comprising SEQ ID NO:_5 or a sequence with at least 98% similarity to SEQ ID NO:_5.

18. The isolated bispecific antibody of claim 15 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain comprising SEQ ID NO:_1 and a heavy chain comprising SEQ ID NO:_5.

19. The isolated bispecific antibody of claim 15 , wherein the anti-CD30 antibody or antigen binding portion thereof is a monoclonal antibody.

20. The isolated bispecific antibody of claim 15 , wherein the anti-CD30 antibody or antigen binding portion thereof is directly or indirectly conjugated to the anti-CD3 antibody or antigen binding portion thereof.

21. The isolated bispecific antibody of claim 20 , wherein the anti-CD30 antibody or antigen binding portion thereof is directly conjugated to the anti-CD3 antibody or antigen binding portion thereof.

22. The isolated bispecific antibody of claim 21 , wherein the anti-CD30 antibody or antigen binding portion thereof is directly conjugated to the anti-CD3 antibody or antigen binding portion thereof via a linker.

23. The isolated bispecific antibody of claim 15 , wherein the anti-CD3 antibody is OKT3 made by hybridoma with ATCC accession number CRL 8001.

24. A composition comprising the isolated bispecific antibody of claim 15 and a pharmaceutically acceptable carrier.

25. An isolated bispecific antibody capable of binding human CD30 and CD3 comprising an anti-CD30 antibody or antigen binding portion thereof and an anti-CD3 antibody or antigen binding portion thereof, wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain variable domain comprising a CDRL1 region comprising the sequence of SEQ ID NO:_10, a CDRL2 region comprising the sequence of SEQ ID NO:_11, and a CDRL3 region comprising the sequence of SEQ ID NO:_12, and a heavy chain variable domain comprising the sequence of SEQ ID NO:_14, a CDRH2 region comprising the sequence of SEQ ID NO:_15, and a CDRH3 region comprising the sequence of SEQ ID NO:16 GAY.

26. The isolated bispecific antibody of claim 25 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain comprising SEQ ID NO:_9 or a sequence with at least 95% similarity to SEQ ID NO:_9, and a heavy chain comprising SEQ ID NO:_13 or a sequence with at least 95% similarity to SEQ ID NO:_13.

27. The isolated bispecific antibody of claim 25 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain comprising SEQ ID NO:_9 or a sequence with at least 98% similarity to SEQ ID NO:_9, and a heavy chain comprising SEQ ID NO:_13 or a sequence with at least 98% similarity to SEQ ID NO:_13.

28. The isolated bispecific antibody of claim 25 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain comprising SEQ ID NO:_9 and a heavy chain comprising SEQ ID NO:_13.

29. The isolated bispecific antibody of claim 25 , wherein the anti-CD30 antibody or antigen binding portion thereof is a monoclonal antibody.

30. The isolated bispecific antibody of claim 25 , wherein the anti-CD30 antibody or antigen binding portion thereof is directly or indirectly conjugated to the anti-CD3 antibody or antigen binding portion thereof.

31. The isolated bispecific antibody of claim 30 , wherein the anti-CD30 antibody or antigen binding portion thereof is directly conjugated to the anti-CD3 antibody or antigen binding portion thereof.

32. The isolated bispecific antibody of claim 31 , wherein the anti-CD30 antibody or antigen binding portion thereof is directly conjugated to the anti-CD3 antibody or antigen binding portion thereof via a linker.

33. The isolated bispecific antibody of claim 25 wherein the anti-CD3 antibody is OKT3 made by hybridoma with ATCC accession number CRL 8001.

34. A composition comprising the isolated bispecific antibody of claim 25 and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2023
From: MEDIN, JEFFREY A.; OLDHAM, ROBYN A.A.
To: MEDICAL COLLEGE OF WISCONSIN, INC.
Reel/Frame 063353/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2023
From: LUM, LAWRENCE G.; THAKUR, ARCHANA
To: UNIVERSITY OF VIRGINIA
Reel/Frame 063354/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2023
From: UNIVERSITY OF VIRGINIA
To: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Reel/Frame 063354/0528 →
Continuity (3)
Continuation 16580625 · Sep 24, 2019
Provisional Application 62735576 · Sep 24, 2018
Related Publication 20230312738A1 · Oct 5, 2023
References Cited (40)
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 11584799B2 · Medin · 2023 [cited by examiner]
US 11667721B2 · Medin · 2023 [cited by examiner]
EP 1870459 · 2016 [cited by applicant]
WO 2003059282 · 2003 [cited by applicant]
WO 2007110205 · 2007 [cited by applicant]
WO 2008119353 · 2008 [cited by applicant]
WO 2009089004 · 2009 [cited by applicant]
WO 2011131746 · 2011 [cited by applicant]
WO 2017066122 · 2017 [cited by applicant]
WO 2018158350 · 2018 [cited by applicant]
Hartmann, F. et al., Anti-CD16/CD30 Bispecific Antibody Treatment for Hodgkin's Disease: Role of Infusion Schedule and Costimulation with Cytokines, Clinical Cancer Research, 2001, 7:1873-1881. [cited by applicant]
Koon, H. et al., Anti-CD30 Antibody-Based Therapy, Current Opinion in Oncology, 2000, 12:588-593. [cited by applicant]
European Patent Office, Communication Pursuant to Article 94(3) EPC, Application No. 19783844.4, May 2, 2024, 7 pages. [cited by applicant]
Bargou, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008; 321(5891), 974-977. [cited by applicant]
Bird et al. Single-chain antigen-binding proteins. Science 1988; 242: 423-426. [cited by applicant]
Carde P, Da Costa L, Manil L, et al. Immunoscintigraphy of Hodgkin's disease: in vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell lines. Eur J Cancer. 1990;26(4):474-479. doi:10.1016/0277-5379(9… [cited by applicant]
Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90: 157-164. [cited by applicant]
Elgundi, et al. The state-of-play and future of antibody therapeutics. Advanced Drug Delivery Reviews 2017. 122: 2-19. [cited by applicant]
Froese et al., Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J Immunol Sep. 15, 1987, 139 (6) 2081-2087. [cited by applicant]
Huston et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Lindhofer et al. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155(1): 219-225. [cited by applicant]
Lum, et al. CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biology of Blood and Marrow Transplantation 2013; 19(6): 925-933. [cited by applicant]
Lum, et al. Targeting T Cells with Bispecific Antibodies for Cancer Therapy. BioDrugs 2011; 25(6): 365-379. [cited by applicant]
Marvin, et al. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin. 2005; 26(6): 649-658. [cited by applicant]
Neut Kolfschoten et al. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange Science. 2007; 317: 1554-7. [cited by applicant]
Nitta, et al. Bispecific F (ab') 2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells. Eur. J. Immunol. 1989.19: 1437-1441. [cited by applicant]
PCT/US2019/052631—International Search Report and Written Opinion, dated Jan. 20, 2020. [cited by applicant]
Perez, et al. Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target Cell Antibodies. J. Exp. Med. 1986; 163: 166-178. [cited by applicant]
Salmeron, et al. A conformational epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies. J. Immunol. 1991; 147: 3047-30… [cited by applicant]
Schwab, U., Stein, H., Gerdes, J. et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299, 65-67 (1982). https://do… [cited by applicant]
Sebastian, et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM× anti-CD3): a phase I study. Cancer Immunol Immunotherapy 2007; 56(10): 1637-1644. [cited by applicant]
Spiess, et al. Alternative molecular formats and therapeutic applications for bispecific antibodies. Molecular Immunology 2015. 67: 95-106. [cited by applicant]
Thakur, et al. Bispecific antibody based therapeutics: Strengths and challenges. Blood Reviews 2018; 32: 339-347. [cited by applicant]
Thakur, et al. Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther. 2010; 12(3): 340-349. [cited by applicant]
Da Costa et al (2000. Cancer Chemother Pharmacol. 46(Suppl): S33-S36). [cited by applicant]
Renner et al, 1995. Immunological Reviews. 145: 179-209. [cited by applicant]
Kuhn et al, 2016. Immunology. 8(8): 889-906. [cited by applicant]
Gillis, 2017. J Allergy Clin Immunol. 139:1253-65. [cited by applicant]
Grudzien et al., 2018. J Immunol Res. pp. 1-11. [cited by applicant]